Sonrai Analytics develops a discovery platform that uses AI and deep learning to enable health, biotech and pharma organisations to filter and transform datasets in real time. Its platform supports client data management, AI-driven imaging workflows and biological interpretation to help research teams identify targets and prioritise therapeutics. The company says customers use the platform to accelerate discovery and improve decision-making in research. Sonrai announced an undisclosed funding round and plans to use the capital to build on its offerings and expand commercial reach. It also announced the hire of former J&J business leader Chris Brooks as chief commercial officer to lead commercial expansion and customer engagement. According to Crunchbase, Sonrai had previously raised £2.8m since being founded in 2018 and is based in Belfast. Sonrai Analytics offers a platform that enables researchers in pharma and biotech to quickly integrate, process and visualize complex, disparate and siloed datasets, shortening timelines and surfacing insights. The platform emphasizes validated data manipulations and regulatory compliance, making it suitable for highly regulated life-science workflows. Sonrai incorporates data visualization and predictive analytics directly into workflows to accelerate organizational processes and improve performance. The company is commercial stage and has been enhancing its product and services in response to customer challenges and expectations. Management says additional capital will strengthen commercial aspirations, allow diversification across market segments, and support acceleration into the U.S. market. There are no revenue or user metrics disclosed in the article. Sonrai Analytics provides an AI cloud data analytics platform that helps precision medicine companies translate complex multi-omics data into real insights for better-personalized treatments. Led by CEO Dr Darragh McArt, the company has placed its platform with key healthcare businesses across the EU and the US. It is entering further key partnerships to scale operations commercially. In June 2022 Sonrai raised £2.175M in a Seed Plus funding round. The company intends to use the funds to accelerate global adoption of its technology and to invest in sales and marketing to scale product adoption by precision medicine companies. Its stated focus is commercial scaling and expanding adoption among precision medicine customers.

Total raised

$3M

Funding rounds

3

Latest round

Seed

Latest activity

Jun 2022